<p>Sutro Biopharma（纳斯达克股票代码：STRO - 获取免费报告）在周五发布的报告中，Citizens Jmp 的股票分析师将其目标价格从 23.00 美元上调至 35.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的价格目标暗示该公司当前价格有 17.63% 的潜在上涨空间。</p>
<p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
<p>其他几位研究分析师也最近对该公司发布了报告。德意志银行将 Sutro Biopharma 的目标价格从 51.00 美元上调至 55.00 美元，并在 3 月 25 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并在 3 月 24 日的研究报告中将其目标价格从 10.00 美元上调至 28.00 美元。富国银行将 Sutro Biopharma 的评级从 “持平” 上调至 “超配”，并在 3 月 24 日的报告中将其目标价格从 8.00 美元上调至 27.00 美元。Leerink Partners 在 4 月 7 日的报告中开始覆盖 Sutro Biopharma 的股票，给予 “表现优于大盘” 的评级，并设定 38.00 美元的目标价格。最后，花旗集团在周五的研究报告中重申了对 Sutro Biopharma 股票的 “表现优于大盘” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价格为 38.88 美元。</p>
<p><strong>查看我们最新的 Sutro Biopharma 股票报告</strong></p>
<h2>Sutro Biopharma 上涨 1.4%</h2>
<p>周五，纳斯达克 STRO 的股票开盘价为 29.76 美元。该公司的 50 日移动平均线为 22.09 美元，200 日移动平均线为 14.61 美元。该公司的市值为 4.9295 亿美元，市盈率为-1.14，贝塔值为 1.31。Sutro Biopharma 的 12 个月低点为 5.23 美元，12 个月高点为 30.50 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近对 STRO 的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Sutro Biopharma 的股份增加了 1,052.8%。AQR Capital Management LLC 目前拥有 1,320,917 股该公司的股票，价值 859,000 美元，此前在上个季度购买了额外的 1,206,330 股。Jane Street Group LLC 在第二季度收购了 Sutro Biopharma 的新股份，价值 492,000 美元。Jacobs Levy Equity Management Inc.在第三季度购买了 Sutro Biopharma 的新股份，价值约 387,000 美元。Two Sigma Investments LP 在第三季度将其在 Sutro Biopharma 的股份增加了 244.8%。Two Sigma Investments LP 目前拥有 396,785 股该公司的股票，价值 345,000 美元，此前在该期间内收购了额外的 281,717 股。最后，Marshall Wace LLP 在第二季度购买了 Sutro Biopharma 的新头寸，价值约 166,000 美元。96.99% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Sutro Biopharma</h2>
<p>（获取免费报告）</p>
<p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化蛋白治疗药物，这在传统的细胞表达系统中可能无法实现。</p>
<p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同阶段的免疫肿瘤候选药物的研发管线。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Sutro Biopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
<p>在你考虑 Sutro Biopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Sutro Biopharma 并不在名单上。</p>
<p>虽然 Sutro Biopharma 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

STRO

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

<p>Citizens Jmp 已将 Sutro Biopharma (NASDAQ:STRO) 的目标价格从 23.00 美元上调至 35.00 美元，维持 “市场表现优于大盘” 的评级。这表明与当前价格相比，潜在上涨幅度为 17.63%。其他分析师也提高了他们的目标价格，德意志银行将其设定为 55.00 美元，HC Wainwright 则为 28.00 美元。该股票目前交易价格为 29.76 美元，市场共识目标价格为 38.88 美元，平均评级为 “适度买入”</p>

<p>Sutro Biopharma (NASDAQ:STRO - Get Free Report) had its price target raised by stock analysts at Citizens Jmp from $23.00 to $35.00 in a report released on Friday,Benzinga reports. The firm presently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's price objective would suggest a potential upside of 17.63% from the company's current price.</p>
<div class="lb-trans"><p>Sutro Biopharma（纳斯达克股票代码：STRO - 获取免费报告）在周五发布的报告中，Citizens Jmp 的股票分析师将其目标价格从 23.00 美元上调至 35.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的价格目标暗示该公司当前价格有 17.63% 的潜在上涨空间。</p>
</div><p>Get <strong>Sutro Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
</div><p>Several other research analysts have also recently issued reports on the company. Deutsche Bank Aktiengesellschaft increased their price objective on Sutro Biopharma from $51.00 to $55.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, March 25th. HC Wainwright upgraded Sutro Biopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and boosted their price target for the company from $10.00 to $28.00 in a research note on Tuesday, March 24th. Wells Fargo &amp; Company raised Sutro Biopharma from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their price objective for the company from $8.00 to $27.00 in a report on Tuesday, March 24th. Leerink Partners started coverage on shares of Sutro Biopharma in a report on Tuesday, April 7th. They set an &#34;outperform&#34; rating and a $38.00 target price for the company. Finally, Citigroup reiterated an &#34;outperform&#34; rating on shares of Sutro Biopharma in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $38.88.</p>
<div class="lb-trans"><p>其他几位研究分析师也最近对该公司发布了报告。德意志银行将 Sutro Biopharma 的目标价格从 51.00 美元上调至 55.00 美元，并在 3 月 25 日的研究报告中给予该股票 “买入” 评级。HC Wainwright 将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并在 3 月 24 日的研究报告中将其目标价格从 10.00 美元上调至 28.00 美元。富国银行将 Sutro Biopharma 的评级从 “持平” 上调至 “超配”，并在 3 月 24 日的报告中将其目标价格从 8.00 美元上调至 27.00 美元。Leerink Partners 在 4 月 7 日的报告中开始覆盖 Sutro Biopharma 的股票，给予 “表现优于大盘” 的评级，并设定 38.00 美元的目标价格。最后，花旗集团在周五的研究报告中重申了对 Sutro Biopharma 股票的 “表现优于大盘” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价格为 38.88 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Sutro Biopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Sutro Biopharma 股票报告</strong></p>
</div><h2>Sutro Biopharma Trading Up 1.4%</h2>
<div class="lb-trans"><h2>Sutro Biopharma 上涨 1.4%</h2>
</div><p>Shares of NASDAQ STRO opened at $29.76 on Friday. The firm has a 50 day moving average of $22.09 and a 200 day moving average of $14.61. The firm has a market capitalization of $492.95 million, a price-to-earnings ratio of -1.14 and a beta of 1.31. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $30.50.</p>
<div class="lb-trans"><p>周五，纳斯达克 STRO 的股票开盘价为 29.76 美元。该公司的 50 日移动平均线为 22.09 美元，200 日移动平均线为 14.61 美元。该公司的市值为 4.9295 亿美元，市盈率为-1.14，贝塔值为 1.31。Sutro Biopharma 的 12 个月低点为 5.23 美元，12 个月高点为 30.50 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in STRO. AQR Capital Management LLC raised its stake in shares of Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock worth $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Sutro Biopharma in the 2nd quarter worth $492,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Sutro Biopharma in the third quarter valued at about $387,000. Two Sigma Investments LP increased its stake in shares of Sutro Biopharma by 244.8% during the third quarter. Two Sigma Investments LP now owns 396,785 shares of the company's stock worth $345,000 after acquiring an additional 281,717 shares during the period. Finally, Marshall Wace LLP purchased a new position in Sutro Biopharma during the second quarter worth about $166,000. 96.99% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对 STRO 的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Sutro Biopharma 的股份增加了 1,052.8%。AQR Capital Management LLC 目前拥有 1,320,917 股该公司的股票，价值 859,000 美元，此前在上个季度购买了额外的 1,206,330 股。Jane Street Group LLC 在第二季度收购了 Sutro Biopharma 的新股份，价值 492,000 美元。Jacobs Levy Equity Management Inc.在第三季度购买了 Sutro Biopharma 的新股份，价值约 387,000 美元。Two Sigma Investments LP 在第三季度将其在 Sutro Biopharma 的股份增加了 244.8%。Two Sigma Investments LP 目前拥有 396,785 股该公司的股票，价值 345,000 美元，此前在该期间内收购了额外的 281,717 股。最后，Marshall Wace LLP 在第二季度购买了 Sutro Biopharma 的新头寸，价值约 166,000 美元。96.99% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Sutro Biopharma</h2>
<div class="lb-trans"><h2>关于 Sutro Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™，设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化蛋白治疗药物，这在传统的细胞表达系统中可能无法实现。</p>
</div><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同阶段的免疫肿瘤候选药物的研发管线。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Sutro Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Sutro Biopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=STRO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
</div><p>Before you consider Sutro Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Sutro Biopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Sutro Biopharma 并不在名单上。</p>
</div><p>While Sutro Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sutro Biopharma 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sutro Biopharma (NASDAQ:STRO) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Market Beat

Sutro Biopharma

Invesco Nasdaq Biotechnology ETF

德意志银行

富国银行

花旗

纳斯达克综合指数

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citizens Jmp 的分析师表示，Sutro Biopharma（纳斯达克代码：STRO）的股价预计将会上涨